{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:36:24Z","timestamp":1793370984218,"version":"4.5.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100012399","name":"HHS | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201600002C"],"award-info":[{"award-number":["HHSO100201600002C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,5,21]]},"abstract":"<jats:p>\n            Ceftobiprole medocaril is an advanced-generation cephalosporin prodrug that has qualified infectious disease product status granted by the US FDA and is currently being evaluated in phase 3 clinical trials in patients with acute bacterial skin and skin structure infections (ABSSSIs) and in patients with\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            bacteremia. In this study, the activity of ceftobiprole and comparators was evaluated against more than 7,300 clinical isolates collected in the United States from 2016 through 2018 from patients with skin and skin structure infections.\n          <\/jats:p>","DOI":"10.1128\/aac.02566-19","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T10:11:05Z","timestamp":1584007865000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":23,"title":["Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018"],"prefix":"10.1128","volume":"64","author":[{"given":"Robert K.","family":"Flamm","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard R.","family":"Duncan","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"Kamal A.","family":"Hamed","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Smart","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"University of Iowa, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/605434"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2007.12.004"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq302"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-227"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S172366"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1509.081228"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143276"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-252"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.05.009"},{"key":"e_1_3_2_12_2","unstructured":"Centers for Disease Control. 2019. Antibiotic resistance threats in the United States. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed November 2019."},{"key":"e_1_3_2_13_2","volume-title":"NUZYRA\u2122 (omadacycline) package insert","author":"Paratek Pharmaceuticals, Inc","year":"2018","unstructured":"Paratek Pharmaceuticals, Inc. 2018. NUZYRA\u2122 (omadacycline) package insert. Paratek Pharmaceuticals, Inc, Boston, MA, USA."},{"key":"e_1_3_2_14_2","unstructured":"Melinta Therapeutics Inc. 2017. Baxdela label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000 208611s000lbl.pdf. Accessed August 2017."},{"key":"e_1_3_2_15_2","unstructured":"Cubist Pharmaceuticals U.S. 2014. SIVEXTRO\u2122 (tedizolid phosphate) label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205435s000lbl.pdf. Accessed June 2019."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1617851"},{"key":"e_1_3_2_17_2","unstructured":"Basilea Medical Ltd. 2014. Zevtera label. https:\/\/www.medicines.org.uk\/emc\/product\/9164\/smpc. Accessed August 06 2019."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu219"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S56616"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0273-x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.13.8.973"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2.1.115"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.825-836.2001"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00029-07"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.02.008"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq397"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01566-18"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.01.015"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/183843"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.10.032"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809040-00004"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.12.020"},{"key":"e_1_3_2_33_2","unstructured":"ClinicalTrials.gov. 2019. Ceftobiprole in the treatment of patients with acute bacterial skin and skin structure infections. Trial NCT03137173. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03137173. Accessed August 31 2019."},{"key":"e_1_3_2_34_2","unstructured":"ClinicalTrials.gov. 2019. Ceftobiprole in the treatment of patients with Staphylococcus aureus bacteremia. Trial NCT03138733. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03138733. Accessed August 30 2019."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy346"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy347"},{"key":"e_1_3_2_37_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 29th informational supplement: M100Ed29","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing: 29th informational supplement: M100Ed29. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_38_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eleventh edition: M07Ed11","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eleventh edition: M07Ed11. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_39_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0 January 2019. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf. Accessed January 2019."},{"key":"e_1_3_2_40_2","unstructured":"U.S. Food and Drug Administration. 2019. Antibacterial susceptibility test interpretive criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria. Accessed 05 May 2019."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02566-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02566-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:43:52Z","timestamp":1645479832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02566-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5,21]]}},"alternative-id":["10.1128\/AAC.02566-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02566-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"assertion":[{"value":"2019-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02566-19"}}